Brief: Everest Medicines' Partner Venatorx Receives FDA Acceptance, Priority Review Of NDA For Cefepime-Taniborbactam

Everest Medicines

15/08/2023 13:14

Aug 15 (Reuters) - Everest Medicines Ltd  1952.HK :
    * EVEREST MEDICINES' PARTNER VENATORX RECEIVES FDA
ACCEPTANCE AND
PRIORITY REVIEW OF NEW DRUG APPLICATION FOR
CEFEPIME-TANIBORBACTAM TO TREAT COMPLICATED URINARY TRACT
INFECTIONS (CUTI)
    * EVEREST MEDICINES LTD - FDA HAS GRANTED PRIORITY REVIEW OF
NDA
WITH A PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE OF FEB.
22, 2024

Source text for Eikon:  ID:nPn57vXf5a 
Further company coverage:  1952.HK 

 ((Reuters.Briefs@thomsonreuters.com;))